摘要
目的了解全新设计的卡铂、希罗达方案用于中晚期宫颈癌新辅助化疗的疗效和安全性。方法将58例FIGO分期为IB2期及以上的宫颈鳞癌患者随机分为卡铂+希罗达组(26例)、顺铂+5-Fu组(22例),经3周期化疗观察两组间疗效和化疗副反应的差异。结果卡铂+希罗达组与顺铂+5-Fu组总有效率差异无显著性意义(69.2%和63.6%,P<0.05),卡铂+希罗达组白细胞下降、静脉炎的发生率显著低于顺铂+5-Fu组,手足综合征虽常见,但易于处理且不影响治疗,其他副反应发生率均较低。结论卡铂+希罗达方案用于中晚期宫颈鳞癌的新辅助化疗疗效确切、安全性好,具有临床应用价值。
Objective To evaluate the efficacy and safety of neoadjuvant chemotherapy based on Carboplatin combined with XELODA in treatment of advanced squamous carcinoma of the uterine cervix. Methods 58 patients with stage beyond IIB1 of the squamous cervical carcinoma were randomized into group A or group B. Group A （26 cases） received neoadjuvant chemotherapy based on earboplatin combined with XELODA. Group B （22 cases） received neoadjuvant chemotherapy based on eisplatin combined with 5 - Fu. After a 3 cycles therapy, we compared the efficacy and side effects of two groups. Results The response rate to the neoadjuvant chemotherapy based on Carboplatin combined with XELODA is similar with neoadjuvant chemotherapy based on eisplatin combined with 5 - Fu （ P 〉 0. 05） . The side effects of it are mild and can be tolerated well. Conclusion Neoadjuvant chemotherapy based on Carboplatin combined with XELODA is safe and efficient treatment for advanced squamous carcinoma of the uterine cervix.
出处
《邯郸医学高等专科学校学报》
2005年第4期286-287,共2页
Journal of Handan Medical College
